Skip to main content
Premium Trial:

Request an Annual Quote

CellMax, Medigen Biotech Partner in Colorectal Cancer Clinical Trials

NEW YORK (GenomeWeb) – Sunnyvale, California-based CellMax Life said today that it has partnered with Taiwan-based Medigen Biotech as part of the firm's cell therapy clinical trials. Medigen will integrate CellMax's CMx circulating tumor cell (CTC) platform with its liquid biopsy panel to examine patient treatment selection and response.

As part of the open-label, multicenter, single arm clinical trial, the team plans to enroll patients with stage II and III colorectal cancer that has separately been surgically resected or in addition to being treated with chemotherapy.

The partners will start the Phase I trial later this year with patients who test positive on the CMx test to receive the natural killer cell therapy treatment. The firms have designed the trial to track patients' cancer status multiple times during treatment, using the CMx blood test to determine treatment response.

CellMax's blood test isolates and analyzes both CTCs and cell-free DNA from a sample of blood to detect six types of analytes, including four classes of genomic mutations, microsatellite instability, and CTCs.

"Colorectal cancer is the second deadliest cancer in the US with 150,000 new cases and $14 billion spent on treatment annually," CellMax Cofounder and CEO Atul Sharan said in a statement. "Medigen's vision to develop innovative cancer therapies especially for the earlier stages of cancer when it is most treatable, is very much aligned to CellMax Life's mission not reduce mortality from colorectal cancer."

Financial details of the agreement were not disclosed.

"Because we expect to recruit patients with early-stage cancer, test sensitivity was the key criteria for platform selection," Medigen Chairman and CEO Stanley Chang said in a statement. "By combining the CMx assay with the CellMax ct-DNA liquid biopsy … we hope to have the most sensitive test for treatment selection and monitoring response."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.